* DIATOS *
1999 - IDF
Paris
www.diatos.com Delivery, Drugs
Key words: Drug delivery, Peptides, Tumor targeting, Cancer, Chemotherapy, Prodrugs, Liposome, Vectocell, DaunoXome
Mission: to research, develop and market targeted anti-cancer drugs based on drug-delivery improvements
Clients: Prescribers
contact@diatos.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Spin-off |
Managing Dir.: Tchélingérian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder)]
Sc.Dir.: Gasmi (Jamal) [M.D. Oncology, Ms. Sciences, ex-Roche, Gustave Roussy]
Fin.Dir.:
SalesMktg: Cowburn (James) [Ph.D. Biochemistry, ex-Zeneus Pharma, Roche, Schering Plough]
BusDev:
Financers: GIMV, InterWest Partners, Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners, NIF, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), Innoven, BFF, Credit Agricole P.E. | Turnover (M€) : 0.30 (2006)
Total funding (M€) : 54.8
Last funding (M€) : 9.4
Focus : Cancers
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .08 | Clinical trial (phase IIa) for DTS-201, a peptidic prodrug of doxorubicin (beginning) | CLIN | [9 years] |
| 2007 .07 | 4th round-financing : 9.4 M€, by Credit Agricole P.E. and previous shareholders | RFIND | [8 years] |
| 2006 .07 | Listing : failure of IPO introduction on Alternext, cancelled due to unfavorable market conditions | PBO | [7 years] |
| 2006 .05 | Licensing-in of specialty cancer product from Gilead | LICIN | [7 years] |
| 2005 .04 | Set-up of US subsidiary in California, USA (Business) | ORGC | [6 years] |
| 2004 .03 | Set-up of subsidiary in Belgium (R&D) | ORGC | [5 years] |
| 2004 .02 | 3rd round-financing : 7.0 M€, by Innoven and BFF (Biotech Fund Flanders) | RFINC | [5 years] |
| 2003 .05 | 2nd round-financing : 9.0 M€, by NIF and Crédit Lyonnais P.E. (today Crédit Agricole P.E.) | RFINB | [4 years] |
| 2003 .04 | Licensing-out of cancer improved-delivery drug development to Medarex | LICOUT | [4 years] |
| 2000 .10 | 1st round-financing : 15.5 M€, led by GIMV and InterWest Partners, with Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners | RFINA | [1 year] |
| 1999 .05 | Seed financing : 1.5 M€, by Sofinnova Partners (subsequently John Tchélingérian joins the company as business developper) | SFIN | [0 year] |
| 1999 .02 | Company founded by Prof. Stratis Avraméas, Dr Thérèse Ternynck, as a spin-off from Institut Pasteur | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
